Development of cetuximab-resistant human nasopharyngeal carcinoma cell lines and mechanisms of drug resistance

被引:16
作者
Zuo, Qiang [1 ]
Shi, Min [1 ]
Li, Libo [1 ]
Chen, Jinzhang [1 ]
Luo, Rongcheng [1 ]
机构
[1] So Med Univ, Dept Oncol, Nanfang Hosp, Guangzhou 510515, Guangdong, Peoples R China
关键词
Cetuximab; Drug resistance; Nasopharyngeal carcinoma; Ras; IGF-1R; PTEN; GROWTH-FACTOR-RECEPTOR; METASTATIC COLORECTAL-CANCER; TRASTUZUMAB RESISTANCE; KINASE INHIBITORS; PLUS CETUXIMAB; BREAST-CANCER; TUMOR-CELLS; PTEN; EXPRESSION; SURVIVIN;
D O I
10.1016/j.biopha.2010.03.003
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
This work aimed to explore the induction of cetuximab-resistant human nasopharyngeal carcinoma (hNPC) 5-8F/Erbitux cells and the mechanisms of drug resistance. The 5-8F cells with high EGFR expression and cetuximab sensitivity were screened and then induced by stepwise exposure to increasing doses of cetuximab. Western blot was conducted to detect protein levels. Our results are as follows: we successfully induced the cetuximab-resistant 5-8F/Erbitux hNPC cells. After treatment with cetuximab for 3 and 5 days, the RI was 1.2 and 1.1, respectively. The 5-8F/Erbitux cells showed cross-resistance to 5-FU (P < 0.01) and some resistance to Taxol (P > 0.05) as well as enhanced sensitivity to DDP (P > 0.05). The cells had increased levels of P-gP, IGF-1R, P-IGF-1R, K-ras, H-ras, and PTEN protein expression (P < 0.001), while survivin decreased (P < 0.001). Through sequence alignments, gene mutations in the PTEN gene at exons 5, 7, and 8, as well as the H-ras and K-ras genes in codons 12, 13, 59, and 61, were not observed. After transfection with H-ras-shRNA plasmid, the 5-8F/Erbitux cells showed reduced levels of gene and protein expression of H-ras and elevated sensitivity to cetuximab. In conclusion, gene amplification and overexpression of H-ras was the major mechanism that caused resistance of 5-8F/Erbitux cells to cetuximab, while the overexpression of the H-ras gene was probably associated with the over-activity of the IGF-1R signaling pathway. Gene deletion or mutation of PTEN was not associated with resistance of 5-8F/Erbitux cells to cetuximab. (C) 2010 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:550 / 558
页数:9
相关论文
共 54 条
[1]   Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy [J].
Ang, KK ;
Andratschke, NH ;
Milas, L .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (03) :959-965
[2]   A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer [J].
Berns, Katrien ;
Horlings, Hugo M. ;
Hennessy, Bryan T. ;
Madiredjo, Mandy ;
Hijmans, E. Marielle ;
Beelen, Karin ;
Linn, Sabine C. ;
Gonzalez-Angulo, Ana Maria ;
Stemke-Hale, Katherine ;
Hauptmann, Michael ;
Beijersbergen, Roderick L. ;
Mills, Gordon B. ;
de Vijver, Marc J. van ;
Bernards, Rene .
CANCER CELL, 2007, 12 (04) :395-402
[3]   Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].
Bonner, JA ;
Harari, PM ;
Giralt, J ;
Azarnia, N ;
Shin, DM ;
Cohen, RB ;
Jones, CU ;
Sur, R ;
Raben, D ;
Jassem, J ;
Ove, R ;
Kies, MS ;
Baselga, J ;
Youssoufian, H ;
Amellal, N ;
Rowinsky, EK ;
Ang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578
[4]  
BOS JL, 1989, CANCER RES, V49, P4682
[5]   PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells [J].
Bouali, Sanae ;
Chretien, Anne-Sophie ;
Ramacci, Carole ;
Rouyer, Marie ;
Becuwe, Philippe ;
Merlin, Jean-Louis .
ONCOLOGY REPORTS, 2009, 21 (03) :731-735
[6]   Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma [J].
Chan, ATC ;
Hsu, MM ;
Goh, BC ;
Hui, EP ;
Liu, TW ;
Millward, MJ ;
Hong, RL ;
Whang-Peng, J ;
Ma, BBY ;
To, KF ;
Mueser, M ;
Amellal, N ;
Lin, X ;
Chang, AY .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3568-3576
[7]   PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival [J].
Chou, Chu-Chung ;
Chou, Ming-Jen ;
Tzen, Chin-Yuan .
MEDICAL ONCOLOGY, 2009, 26 (03) :322-326
[8]   Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy [J].
Chua, DTT ;
Nicholls, JM ;
Sham, JST ;
Au, GKH .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (01) :11-20
[9]   Drug therapy: EGFR antagonists in cancer treatment [J].
Ciardiello, Fortunato ;
Tortora, Giampaolo .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (11) :1160-1174
[10]  
Coutinho C M, 1999, Sao Paulo Med J, V117, P113